English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduVijay Goradia, a Houston-based businessman, philanthropist, and cancer survivor, has donated $10 million to The University of Texas MD Anderson Cancer Center to speed translational research and clinical trials.
Tag: Cellular Therapy
Chula Makes Progress in “CAR T-Cell Therapy” Innovation: New Hope for Thai Lymphoma Cancer Patients
Chulalongkorn University, Thailand, and Nagoya University, Japan, in their collaboration to develop an immunotherapy method for curing cancer, reported on the progress of CAR T-cell immunotherapy innovation for treating cancer in leukemia and B-cell lymphoma patients, which can increase survival rates and reduce cancer recurrence.
UChicago Medicine earns high marks for stem cell transplant survival rates
New data show the University of Chicago Medicine’s David and Etta Jonas Center for Cellular Therapy has the highest one-year survival rate in Illinois for adults undergoing blood and bone marrow stem cell transplants. UChicago Medicine had an 80% one-year survival rate among adult stem cell patients, according to the latest statistics released in mid-December by the Center for International Blood & Marrow Transplant Research (CIBMTR).
NCCN Annual Congress on Hematologic Malignancies™ Returns to In-Person October 14–15, 2022 in New York City
The 2022 NCCN Annual Congress on Hematologic Malignancies™ (#NCCNhem22) is taking place Friday, October 14–Saturday, October 15, 2022 in New York City. All live sessions will also stream remotely through a virtual event platform.
Penn Medicine and Children’s Hospital of Philadelphia Announce Partnership with Costa Rica for CAR T Cell Therapy
Penn Medicine and Children’s Hospital of Philadelphia (CHOP), who together pioneered the research and development of the world’s first personalized cellular therapy for cancer — also known as CAR T cell therapy — have announced plans with Costa Rica’s CCSS, or the Caja Costarricense de Seguro Social (Social Security Program), to facilitate CAR T research in Costa Rica.
Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai
Internationally recognized hematologist John P. Chute, MD, has been selected to direct the Division of Hematology and Cellular Therapy in the Department of Medicine at Cedars-Sinai Cancer. The physician-scientist also will serve as director of the Center for Myelodysplastic Diseases Research and associate director of the Board of Governors Regenerative Medicine Institute in the Department of Biomedical Sciences.
Penn Study Supports Use of Radiation Before CAR Therapy for Multiple Myeloma
Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy.
MD Anderson and Allogene Therapeutics announce strategic collaboration to accelerate advancement of allogeneic CAR T therapy (AlloCAR T)
MD Anderson and Allogene today announced a strategic five-year collaboration for preclinical and clinical investigation of allogeneic CAR T cell therapies.
Roswell Park Study: Delaying Antiviral Treatment May Boost Immunity in Stem Cell Transplant Recipients
Patients who develop cytomegalovirus infections after allogeneic stem cell transplantation may be able to develop an immunity against the virus, strengthen their immune system and reduce reliance on strong antiviral medications, a team from Roswell Park reports in the journal Biology of Blood and Marrow Transplantation.
Rapid Growth in Global Development of Cancer Cellular Immunotherapies Highlighted by Latest Report from Cancer Research Institute and GlobalData
A new report, published in Nature Reviews Drug Discovery, reveals that the cellular immunotherapy landscape continues to expand, with 472 more cellular therapies in development now than one year ago
$10 million gift accelerates research to improve cancer therapies, extend benefits to more patients
The David and Etta Jonas Center for Cellular Therapy is being established at the University of Chicago Medicine to accelerate research in hard-to-treat cancers.
MD Anderson and Takeda Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform
MD Anderson and Takeda today announced an exclusive license agreement and research agreement to develop CAR NK-cell therapies for the the treatment of B-cell malignancies.